{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T11:50:34Z","timestamp":1720353034697},"reference-count":47,"publisher":"Impact Journals, LLC","issue":"63","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,12,5]]},"DOI":"10.18632\/oncotarget.21990","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T16:21:40Z","timestamp":1508862100000},"page":"107283-107294","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease"],"prefix":"10.18632","volume":"8","author":[{"given":"Mei-Yi","family":"Wu","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan"},{"name":"Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Medical University, Shuang Ho Hospital, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Hung","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Education, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Chun","family":"Wu","sequence":"additional","affiliation":[{"name":"Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[{"name":"Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Der-Cherng","family":"Tarng","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan"},{"name":"Department and Institute of Physiology, National Yang-Ming University, Taipei, Taiwan"},{"name":"Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,10,20]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Chertow","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1681\/ASN.2012070713","article-title":"Mineral metabolites and CKD progression in African Americans","volume":"24","author":"Wolf","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1681\/ASN.V132504","article-title":"Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States:results from the Third National Health and Nutrition Examination Survey","volume":"13","author":"Curhan","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1681\/ASN.2005090997","article-title":"Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients","volume":"17","author":"Kalantar-Zadeh","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Lin","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/ki.2012.270","article-title":"Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s)","volume":"82","author":"Parfrey","year":"2012","journal-title":"Kidney Int"},{"key":"7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.semnephrol.2006.05.009","article-title":"Iron supplementation in renal anemia","volume":"26","author":"Fishbane","year":"2006","journal-title":"Semin Nephrol"},{"key":"8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/ki.2013.185","article-title":"Use of phosphate-binding agents is associated with a lower risk of mortality","volume":"84","author":"Teplan","year":"2013","journal-title":"Kidney Int"},{"key":"9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","author":"Kidney Disease:Improving Global Outcomes CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10","doi-asserted-by":"publisher","first-page":"c108","DOI":"10.1159\/000337087","article-title":"Non-calcium-containing phosphate binders:comparing efficacy, safety, and other clinical effects","volume":"120","author":"Adragao","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000348805","article-title":"Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification","volume":"37","author":"Miyamoto","year":"2013","journal-title":"Am J Nephrol"},{"key":"12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","article-title":"KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD","volume":"62","author":"Szczech","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"13","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease:Improving Global Outcomes guidelines on anaemia management in chronic kidney disease:a European Renal Best Practice position statement","volume":"28","author":"Cochat","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000344008","article-title":"Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients:results of a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Kumagai","year":"2012","journal-title":"Am J Nephrol"},{"key":"15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2215\/CJN.05170513","article-title":"Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD","volume":"9","author":"Block","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"16","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/ndt\/gft483","article-title":"A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis","volume":"29","author":"Hirakata","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ndt\/17.2.265","article-title":"An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients:ferric citrate","volume":"17","author":"Hsu","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1053\/j.ajkd.2015.03.013","article-title":"The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients:Results From Prespecified Analyses of a Randomized Clinical Trial","volume":"66","author":"Goral","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Blumenthal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40620-014-0108-6","article-title":"Effect of oral ferric citrate on serum phosphorus in hemodialysis patients:multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Wu","year":"2015","journal-title":"J Nephrol"},{"key":"21","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia","volume":"28","author":"Chertow","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5","volume":"65","author":"Chertow","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"23","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease:an updated systematic review and meta-analysis","volume":"382","author":"Tsuyuki","year":"2013","journal-title":"Lancet"},{"key":"24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1310\/hpj5002-139","article-title":"Ferric citrate","volume":"50","author":"Baker","year":"2015","journal-title":"Hosp Pharm"},{"key":"25","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1681\/ASN.V1061274","article-title":"New phosphate binding agents:ferric compounds","volume":"10","author":"Young","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ki.2008.130","article-title":"Hyperphosphatemia of chronic kidney disease","volume":"74","author":"Pratt","year":"2008","journal-title":"Kidney Int"},{"key":"27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1681\/ASN.2008040349","article-title":"Association of serum phosphate with vascular and valvular calcification in moderate CKD","volume":"20","author":"Kestenbaum","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"28","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Mannstadt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"29","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Investigators","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"He","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Wolf","year":"2008","journal-title":"N Engl J Med"},{"key":"32","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Ojo","year":"2011","journal-title":"JAMA"},{"key":"33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients:a new target in CKD-MBD therapy?","volume":"5","author":"Moyses","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"34","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","article-title":"Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients","volume":"26","author":"Ortiz","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients:a randomized clinical trial","volume":"59","author":"Zoccali","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"36","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"Wolf","year":"2012","journal-title":"Kidney Int"},{"key":"37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfg458","article-title":"Anaemia in haemodialysis patients of five European countries:association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"19","author":"Held","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-6386(96)90130-4","article-title":"The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease","volume":"28","author":"Barre","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"39","doi-asserted-by":"publisher","first-page":"CD010590","DOI":"10.1002\/14651858.CD010590.pub2","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease:a network meta-analysis","author":"Strippoli","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"40","doi-asserted-by":"publisher","first-page":"c95","DOI":"10.1159\/000345158","article-title":"Treatment of anaemia with erythropoiesis-stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk:a meta-analysis","volume":"121","author":"Vaz","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nrneph.2010.139","article-title":"Iron supplementation to treat anemia in patients with chronic kidney disease","volume":"6","author":"Coyne","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"42","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1681\/ASN.2007101084","article-title":"Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients","volume":"19","author":"Tarng","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/ndt\/gft269","article-title":"Iron toxicity:relevance for dialysis patients","volume":"29","author":"Vaziri","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.jrn.2007.10.009","article-title":"Intravenous iron, inflammation, and oxidative stress:is iron a friend or an enemy of uremic patients?","volume":"18","author":"Garneata","year":"2008","journal-title":"J Ren Nutr"},{"key":"45","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1681\/ASN.2014080842","article-title":"Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD","volume":"26","author":"Koury","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"46","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1053\/j.ajkd.2012.11.041","article-title":"Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients:a short-term randomized trial","volume":"61","author":"Lewis","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"47","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement","volume":"6","author":"Group","year":"2009","journal-title":"PLoS Med"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T06:01:51Z","timestamp":1659679311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,20]]},"references-count":47,"journal-issue":{"issue":"63","published-print":{"date-parts":[[2017,12,5]]}},"alternative-id":["21990","29291028"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.21990","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,20]]}}}